289 related articles for article (PubMed ID: 15633211)
1. Clinicopathological and prognostic implications of endoglin (CD105) expression in hepatocellular carcinoma and its adjacent non-tumorous liver.
Ho JW; Poon RT; Sun CK; Xue WC; Fan ST
World J Gastroenterol; 2005 Jan; 11(2):176-81. PubMed ID: 15633211
[TBL] [Abstract][Full Text] [Related]
2. Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF.
Yao Y; Pan Y; Chen J; Sun X; Qiu Y; Ding Y
Ann Clin Lab Sci; 2007; 37(1):39-48. PubMed ID: 17311868
[TBL] [Abstract][Full Text] [Related]
3. [Tumor microvascular density detected by anti-CD105 and anti-CD34 in hepatocellular carcinoma patients and its predictive value of tumor recurrence after liver transplantation].
Wang Y; Zhang XH; Guo P; Yan LN; He D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 41(5):818-21. PubMed ID: 21302449
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor-beta binding receptor endoglin (CD105) expression in esophageal cancer and in adjacent nontumorous esophagus as prognostic predictor of recurrence.
Bellone G; Solerio D; Chiusa L; Brondino G; Carbone A; Prati A; Scirelli T; Camandona M; Palestro G; Dei Poli M
Ann Surg Oncol; 2007 Nov; 14(11):3232-42. PubMed ID: 17682823
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody.
Tanaka F; Otake Y; Yanagihara K; Kawano Y; Miyahara R; Li M; Yamada T; Hanaoka N; Inui K; Wada H
Clin Cancer Res; 2001 Nov; 7(11):3410-5. PubMed ID: 11705856
[TBL] [Abstract][Full Text] [Related]
6. Correlation between apoptotic index and angiogenesis in non-small cell lung cancer: comparison between CD105 and CD34 as a marker of angiogenesis.
Tanaka F; Otake Y; Yanagihara K; Kawano Y; Miyahara R; Li M; Ishikawa S; Wada H
Lung Cancer; 2003 Mar; 39(3):289-96. PubMed ID: 12609567
[TBL] [Abstract][Full Text] [Related]
7. Endoglin (CD 105) as a potential prognostic factor in neuroblastoma.
Ćavar S; Jelašić D; Seiwerth S; Milošević M; Hutinec Z; Mišić M
Pediatr Blood Cancer; 2015 May; 62(5):770-5. PubMed ID: 25683142
[TBL] [Abstract][Full Text] [Related]
8. Particular distribution and expression pattern of endoglin (CD105) in the liver of patients with hepatocellular carcinoma.
Yu D; Zhuang L; Sun X; Chen J; Yao Y; Meng K; Ding Y
BMC Cancer; 2007 Jul; 7():122. PubMed ID: 17608955
[TBL] [Abstract][Full Text] [Related]
9. Microvascular density of regenerative nodule to small hepatocellular carcinoma by automated analysis using CD105 and CD34 immunoexpression.
Paschoal JP; Bernardo V; Canedo NH; Ribeiro OD; Caroli-Bottino A; Pannain VL
BMC Cancer; 2014 Feb; 14():72. PubMed ID: 24507660
[TBL] [Abstract][Full Text] [Related]
10. Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma.
Yang LY; Lu WQ; Huang GW; Wang W
BMC Cancer; 2006 May; 6():110. PubMed ID: 16650286
[TBL] [Abstract][Full Text] [Related]
11. Endoglin (CD 105) is expressed on endothelial cells in the primary central nervous system lymphomas and correlates with survival.
Sugita Y; Takase Y; Mori D; Tokunaga O; Nakashima A; Shigemori M
J Neurooncol; 2007 May; 82(3):249-56. PubMed ID: 17102906
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome.
Martone T; Rosso P; Albera R; Migliaretti G; Fraire F; Pignataro L; Pruneri G; Bellone G; Cortesina G
Oral Oncol; 2005 Feb; 41(2):147-55. PubMed ID: 15695116
[TBL] [Abstract][Full Text] [Related]
13. Thymidine phosphorylase (platelet-derived endothelial cell growth factor), microvessel density and clinical outcome in hepatocellular carcinoma.
Yamamoto A; Dhar DK; El-Assal ON; Igarashi M; Tabara H; Nagasue N
J Hepatol; 1998 Aug; 29(2):290-9. PubMed ID: 9722211
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis in superficial esophageal squamous cell carcinoma: assessment of microvessel density based on immunostaining for CD34 and CD105.
Kumagai Y; Sobajima J; Higashi M; Ishiguro T; Fukuchi M; Ishibashi K; Baba H; Mochiki E; Yakabi K; Kawano T; Tamaru J; Ishida H
Jpn J Clin Oncol; 2014 Jun; 44(6):526-33. PubMed ID: 24748644
[TBL] [Abstract][Full Text] [Related]
15. Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors.
Basilio-de-Oliveira RP; Pannain VL
World J Gastroenterol; 2015 Jun; 21(22):6924-30. PubMed ID: 26078569
[TBL] [Abstract][Full Text] [Related]
16. Microvessel density assessment in benign and malignant endometrial changes.
Czekierdowski A; Czekierdowska S; Czuba B; Cnota W; Sodowski K; Kotarski J; Zwirska-Korczala K
J Physiol Pharmacol; 2008 Sep; 59 Suppl 4():45-51. PubMed ID: 18955753
[TBL] [Abstract][Full Text] [Related]
17. Microvessel Landscape Assessment in Pancreatic Ductal Adenocarcinoma: Unclear Value of Targeting Endoglin (CD105) as Prognostic Factor of Clinical Outcome.
Lytras D; Leontara V; Kefala M; Foukas PG; Giannakou N; Pouliakis A; Dervenis C; Panayiotides IG; Karakitsos P
Pancreas; 2015 Jan; 44(1):87-92. PubMed ID: 25058886
[TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of CD105-assessed microvessel density in laryngeal carcinoma.
Zvrko E; Mikic A; Vuckovic L; Djukic V; Knezevic M
Otolaryngol Head Neck Surg; 2009 Oct; 141(4):478-83. PubMed ID: 19786216
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions.
Ding S; Li C; Lin S; Yang Y; Liu D; Han Y; Zhang Y; Li L; Zhou L; Kumar S
Hum Pathol; 2006 Jul; 37(7):861-6. PubMed ID: 16784986
[TBL] [Abstract][Full Text] [Related]
20. Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas.
Barresi V; Cerasoli S; Vitarelli E; Tuccari G
Acta Neuropathol; 2007 Aug; 114(2):147-56. PubMed ID: 17594108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
